MTP-1307, a novel antidiabetic agent, improves the glucose intolerance of viable yellow obese-diabetic mice.
MTP-1307 is an oral antidiabetic agent with a unique profile. It improves the glucose intolerance of viable yellow obese-diabetic mice at 25 mg/kg whereas at 300 mg/kg, it only marginally lowers the basal glucose levels of the same mice. This selective activity on exogenous glucose makes MTP-1307 potentially a useful agent to treat postprandial glucose intolerance without causing hypoglycemia.
Yen
T T
TT
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D005215:Fasting; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007700:Kinetics; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008817:Mice, Mutant Strains; D009765:Obesity; D011743:Pyrimidines / Q000627:therapeutic use*; D014044:Tolbutamide / Q000627:therapeutic use
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D011743:Pyrimidines; C054187:MTP 1307; D014044:Tolbutamide